Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BMS-813160

Small molecule · Antagonist of CCR2 and CCR5 · developed by BRISTOL MYERS SQUIBB

Phase 2 Most advanced trial

BMY Developer

1 Registered trials

What is BMS-813160?

BMS-813160 is a small-molecule antagonist of CCR2 and CCR5, chemokine receptors expressed on monocytes, macrophages, and certain cancer cells. It blocks CCR2/CCR5-mediated signaling to inhibit inflammatory processes, angiogenesis, tumor cell migration, proliferation, and invasion. The drug is studied in non-small cell lung cancer and hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: CCR2, CCR5
Mechanism: Antagonist of CCR2 and CCR5
Pathways: inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation
Therapy area: Oncology
Developer: BRISTOL MYERS SQUIBB (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 83U7957287

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04123379	Phase 2	Non-small Cell Lung Cancer	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular CarcinomaNon-small Cell Lung Cancer

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind BMS-813160

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z